NYSE: BHVN

Biohaven Ltd.

Healthcare | Biotechnology

No licensed closing price on file for BHVN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Biohaven Ltd. (NYSE: BHVN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:57 UTC.

What Biohaven Ltd. does

Biohaven is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in immunology, neuroscience, and oncology. The company became an independent, publicly traded entity in October 2022 following a spin-off from its former parent company. Biohaven is prioritizing three key late-stage clinical programs: Kv7 ion channel modulation for epilepsy, MoDE and TRAP extracellular protein degraders for immunological diseases, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases including obesity.

Summarized from Biohaven Ltd.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for BHVN are available in Oxford Ledge.
Open BHVN in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-17

2026-09-17SVP, Clinical OperationsStock Options (Right to buy)Award1,000—
2026-04-30DirectorStock Options (Right to buy)Award68,693—
2026-04-30DirectorStock Options (Right to buy)Award68,693—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.13,210,585$196.57M+17.7%
MONTANOVA CAPITAL, LLC10,286,937$153.07M0.0%
STIFEL FINANCIAL CORP9,941,165$147.92M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2023-05-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Yahoo2026-10-10
Biohaven partners with Ono in $100m IgG degrader deal
Yahoo2026-10-09
Biohaven licenses IgG degrader portfolio to Japan’s Ono
Seeking Alpha Markets2026-10-08
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
prnewswire.com2026-10-08
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Benzinga2026-10-08POS

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BHVN and 5,000+ tickers.

Create a free account — keep BHVN

For your agent

GET /api/data?ticker=BHVN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt